Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery
World Journal of Surgery · 2025-03 · 49 (3) · 698-707
DOI: 10.1002/wjs.12484 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgery, online erschienen am 09.01.2025. Verfasst von Zayed Rashid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Postoperative Complications, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Preoperative Care. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are increasingly being used for the management of diabetes mellitus and obesity. We sought to define the impact of preoperative GLP‐1RA use on outcomes following major surgical procedures.
Methods
Patients who underwent a major surgical procedure between 2013 and 2021 were identified using the IBM MarketScan database. Patients who took GLP‐1RA within a year before surgery were categorized as “exposed.” After propensity score matching (PSM), multivariable regression analysis was used to define the association of GLP‐1RA exposure with postoperative complications.
Results
Among 138,980 patients (coronary artery bypass graft: n = 39,516, 28.4%; pneumonectomy: n = 4,881, 3.5%; abdominal aortic aneurysm repair: 4,459, 3.3%; pancreatectomy: n = 15,873, 11.4%; and colectomy: n = 74,251, 53.4%), most individuals were male ( n = 80,871, 58.2%) with a median age of 58 (IQR 53–61) years. 2944 (2.2%) individuals had GLP‐1RA exposure before surgery. Overall incidence of complications was 36.5% ( n = 50,724); complications included sepsis ( n = 6,385, 4.6%), surgical site infections ( n = 7,431, 5.3%), thromboembolism ( n = 3,609, 2.6%), pneumonia ( n = 4,783, 3.4%), renal ( n = 9,017, 6.5%), or cardiopulmonary failure ( n = 26,661, 19.2%). On unmatched analysis, patients on GLP‐1RA had a higher risk of complications (no GLP‐1RA: 36.3% vs. GLP‐1RA: 44.5% p < 0.001); however, after PSM to account for measured confounders, GLP‐1RA exposure was not associated with the odds of surgical complications (OR 0.99 95% CI 0.91–1.08; p > 0.05). Among patients using GLP‐1RA during the 2 weeks before surgery ( n = 522, 17.7%), there was no association of GLP‐1RA with risk of complications (nonrecent GLP‐1RA: 44.7% vs. recent GLP‐1RA: 44.1%; p = 0.992).
Conclusions
GLP‐1RA use was not associated with an increased risk of complications following major surgical procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
- Department of Internal Medicine, Division of Palliative Care, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
ORCID-Profile: Timothy M Pawlik
Zitieren
APA
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Kawashima, J., Mumtaz, K., & Pawlik, T. M. (2025). Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery. World Journal of Surgery, 49(3), 698-707. https://doi.org/10.1002/wjs.12484
Vancouver
Rashid Z, Woldesenbet S, Khalil M, Altaf A, Kawashima J, Mumtaz K, et al. Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery. World Journal of Surgery. 2025;49(3):698-707. doi:10.1002/wjs.12484
BibTeX
@article{Rashid2025,
author = {Rashid, Zayed and Woldesenbet, Selamawit and Khalil, Mujtaba and Altaf, Abdullah and Kawashima, Jun and Mumtaz, Khalid and Pawlik, Timothy M},
title = {Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery},
journal = {World Journal of Surgery},
year = {2025},
volume = {49},
number = {3},
pages = {698--707},
doi = {10.1002/wjs.12484}
}
EUVIMED